上海心玮医疗科技股份有限公司（心玮医疗-B）董事会已批准一项H股回购计划。根据该计划，公司获授权动用不超过1亿港元资金，在公开市场购回最多100万股H股。
此项回购计划旨在优化公司资本结构，提升每股收益，并彰显管理层对公司未来发展的信心。回购行动将在符合香港联合交易所有限公司证券上市规则及相关法律法规的前提下进行。
上海心玮医疗科技股份有限公司（心玮医疗-B）董事会已批准一项H股回购计划。根据该计划，公司获授权动用不超过1亿港元资金，在公开市场购回最多100万股H股。
此项回购计划旨在优化公司资本结构，提升每股收益，并彰显管理层对公司未来发展的信心。回购行动将在符合香港联合交易所有限公司证券上市规则及相关法律法规的前提下进行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.